Literature DB >> 1491384

Autoantibodies to lipocortin-1 are associated with impaired glucocorticoid responsiveness in rheumatoid arthritis.

M R Podgorski1, N J Goulding, N D Hall, R J Flower, P J Maddison.   

Abstract

Autoantibodies to the antiinflammatory protein lipocortin-1 have been found in patients with rheumatoid arthritis (RA) receiving oral glucocorticoids. The highest antibody titers correlated with a requirement for high maintenance doses of steroid (> 7.5 mg/day prednisolone). Forty-two patients with RA were grouped according to high or low autoantibody titer. In 18 patients, peripheral blood leukocyte counts and phenotypic analysis were performed before and 4 h after a single intravenous (iv) dose of 100 mg hydrocortisone. The group with low titer antibody exhibited a normal poststeroid peripheral blood lymphopenia, but the response in the group with high antibody titer was considerably blunted. In a 2nd study, 24 patients received 3 separate doses of 1000 mg iv methylprednisolone. After 8 weeks the group with the high titer antibody had shown no improvements in clinical or laboratory variables observed in the group with low titer antibody. Thus, the presence of high titer antilipocortin-1 antibody is associated with impaired responses to glucocorticoid therapy both in terms of clinical efficacy and effects on the immune system. This could explain the relative glucocorticoid resistance reported in a proportion of patients with RA.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1491384

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  11 in total

1.  Annexin V autoantibodies in rheumatoid arthritis.

Authors:  M I Rodríguez-García; J A Fernández; A Rodríguez; M P Fernández; C Gutierrez; J C Torre-Alonso
Journal:  Ann Rheum Dis       Date:  1996-12       Impact factor: 19.103

Review 2.  Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses.

Authors:  J A Da Silva
Journal:  Ann Rheum Dis       Date:  1995-01       Impact factor: 19.103

3.  Study of the Annexin A1 and Its Associations with Carcinoembryonic Antigen and Mismatch Repair Proteins in Colorectal Cancer.

Authors:  Lenuce Ribeiro Aziz Ydy; Gilmar Ferreira do Espírito Santo; Ivana de Menezes; Michelle Santos Martins; Eliane Ignotti; Amílcar Sabino Damazo
Journal:  J Gastrointest Cancer       Date:  2016-03

4.  Glucocorticoid inhibition of adjuvant arthritis synovial macrophage nitric oxide production: role of lipocortin 1.

Authors:  Y H Yang; P Hutchinson; L L Santos; E F Morand
Journal:  Clin Exp Immunol       Date:  1998-01       Impact factor: 4.330

5.  An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer.

Authors:  F M Brichory; D E Misek; A M Yim; M C Krause; T J Giordano; D G Beer; S M Hanash
Journal:  Proc Natl Acad Sci U S A       Date:  2001-08-14       Impact factor: 11.205

6.  Increased susceptibility of annexin-A1 null mice to nociceptive pain is indicative of a spinal antinociceptive action of annexin-A1.

Authors:  S S Ayoub; S Yazid; R J Flower
Journal:  Br J Pharmacol       Date:  2008-05-12       Impact factor: 8.739

7.  Lipocortin 1 mediates the inhibition by dexamethasone of the induction by endotoxin of nitric oxide synthase in the rat.

Authors:  C C Wu; J D Croxtall; M Perretti; C E Bryant; C Thiemermann; R J Flower; J R Vane
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

Review 8.  Annexin-A1: a pivotal regulator of the innate and adaptive immune systems.

Authors:  F D'Acquisto; M Perretti; R J Flower
Journal:  Br J Pharmacol       Date:  2008-07-21       Impact factor: 8.739

9.  Differential distribution of annexins-I, -II, -IV, and -VI in synovium.

Authors:  N J Goulding; J Dixey; E F Morand; R A Dodds; L S Wilkinson; A A Pitsillides; J C Edwards
Journal:  Ann Rheum Dis       Date:  1995-10       Impact factor: 19.103

10.  Macrophages in synovial inflammation.

Authors:  Aisling Kennedy; Ursula Fearon; Douglas J Veale; Catherine Godson
Journal:  Front Immunol       Date:  2011-10-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.